Acanthosis nigricans
☆ AI Dermatology — Free Service
Saksamaa 2022. aasta Stiftung Warentesti tulemustes oli tarbijate rahulolu ModelDermiga vaid veidi madalam kui tasuliste telemeditsiini konsultatsioonidega.
Saksamaa 2022. aasta Stiftung Warentesti tulemustes oli tarbijate rahulolu ModelDermiga vaid veidi madalam kui tasuliste telemeditsiini konsultatsioonidega.
See esineb sageli rasvunud inimestel.
relevance score : -100.0%
ReferencesAcanthosis nigricans on aluseks oleva haigusseisundi naha ilming. See ilmub sageli nahavoltides, nagu kael, kaenlaalused ja kubemes, ning näeb välja nagu sametine tumedate laigud, mille servad on ebaselged. See seisund on tavaliselt seotud diabeedi ja insuliiniresistentsusega, kuid harvadel juhtudel võib see viidata kehasisesele vähile. See võib ilmneda ka hormoonprobleemide või teatud ravimite, näiteks steroidide ja rasestumisvastaste pillide kasutamise tõttu.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans (AN) on tavaline nahahaigus, mis on seotud mitmesuguste terviseprobleemidega, nagu insuliiniresistentsus, diabeet, rasvumine, teatud vähivormid, hormonaalsed probleemid ja ravimite reaktsioonid. AN ravimine keskendub põhiliste terviseprobleemide lahendamisele. Esialgu kontrollivad arstid insuliiniresistentsuse tunnuseid, mis hõlmavad rasvumist, kõrget kolesteroolitaset, kõrget vererõhku ja 2. tüüpi diabeeti. Arstid määravad sageli esimese ravivalikuna topical retinoids, mis võivad aidata naha paksenemist. Siiski ei pruugi need naha tumenemist täielikult lahendada. Ka teised ravivõimalused, nagu salicylic acid, podophyllin, urea ja calcipotriol, vajavad sagedast kasutamist.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
○ Põhjused
See esineb tavaliselt alla 40‑aastastel inimestel, võib olla geneetiliselt päritud ning on seotud rasvumise või endokrinopaatiaga, nagu hüpotüreoidism, akromegaalia, polütsüstiliste munasarjade sündroom, insuliiniresistentne diabeet või Cushingi sündroom.
○ Ravi ― OTC ravimid
#40% urea cream